24 results
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
12 Jul 23
Report of Foreign Private Issuer
12:00am
capital objectives, such as employee satisfaction, employee retention and employee training and leadership programs
The target annual cash bonus
10-K
2022 FY
EX-14.1
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
in training programs provided by the Company covering broad ranges of activities. The Company maintains a Quality Management System that documents all
10-K
2022 FY
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
guides, communication plans for healthcare professionals and ETASU. ETASU can include, but are not limited to, special training or certification … on an ongoing basis with cGMP. In complying with cGMP, we must expend time, money and effort in the areas of training, production and quality control
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
12 Apr 22
Report of Foreign Private Issuer
4:15pm
performed three years of post-doctoral training in pediatrics and pediatric infectious diseases and immunology at NYU-Bellevue Medical Center
6-K
EX-99.1
zxpq1ckx wmwoplxyr
2 Dec 21
BiondVax announces Third Quarter 2021 Financial Results and Provides Business Update
4:15pm
6-K
EX-99.1
nta atkiwm
22 Nov 21
Report of Foreign Private Issuer
6:05am
6-K
EX-99.1
0sig43w7n mvsi9to
25 Feb 20
Report of Foreign Private Issuer
12:41pm
6-K
EX-99.1
5oct012llxe5s0xo2t0
13 Jan 20
Report of Foreign Private Issuer
6:24am
F-1/A
cxhibj
7 Jun 19
Registration statement (foreign) (amended)
11:42am
F-1/A
bzrk82e9wwz 9qnqz
6 Jun 19
Registration statement (foreign) (amended)
12:00am
F-1/A
uitju8 6el
30 May 19
Registration statement (foreign) (amended)
8:46am
F-1/A
viq40c
6 May 19
Registration statement (foreign) (amended)
10:03am
F-1
f98eako2kbjcqc
25 Mar 19
Registration statement (foreign)
4:08pm